RussianPatents.com

Pharmaceutical composition for treating anxiety. RU patent 2444369.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a composition for treating anxiety disorder. The pharmaceutical composition for treating anxiety disorder containing ginsenoside having Rg1 and Rb1; and a glycyrrhizic acid derivative being specified in a group consisting of glycyrrhizic acid, glycyrrhetinic acid and their combination taken in specific proportions. The pharmaceutical composition for treating anxiety disorder containing ginseng and liquorice taken in certain proportions.

EFFECT: compositions are effective for treating anxiety disorder.

8 cl, 6 dwg, 2 tbl, 22 ex

IPC classes for russian patent Pharmaceutical composition for treating anxiety. RU patent 2444369. (RU 2444369):

A61P25/22 - Anxiolytics

A61K36/725 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/484 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/258 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

Method of individual psychologic rehabilitation of patients with prosthetic heart valves / 2444288
Invention relates to medicine, cardiology and cardiac surgery, and can be used for psychological rehabilitation of patients with prosthetic heart valves (PHV). Method includes studying index of development of anxious disorders in pre-operational and post-operational periods and carrying out procedures for patients who have undergone cardiosurgical operations, including drug therapy. In determination of anxiety higher level is considered to be from 31 points and higher, additionally performed are point massage and muscular relaxation successively with groups of muscles of arms, forearms, face, neck, shoulder girdle, abdomen, hips, ankles and feet. Relaxation with each group of muscles is performed for 5-10 seconds 2-3 times per week.

Composition for injections based on crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2h-1,4-benzodiazepin-2-one exhibiting tranquilising action and method for preparing it / 2440120
Group of inventions relates to medicine, in particular to pharmacy. A composition for injections exhibiting tranquilising action contains the ingredients in the following proportions, wt %: crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one - 0.05-0.15, polyvinylpyrrolidone - 0.50-1.20, "Tween-80" - 2.00-10.00, glycerine - 5.00-15.00, sodium pyrosulphite - 0.30-1.20, sodium hydrate solution - to pH 6.0-7.5, water - the rest. A method for preparing the composition consist in the fact that "Tween-80" and glycerine are mixed, heated to 70-90°C, and crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one is dissolved. The prepared mixture is poured in the mixed aqueous solution of sodium pyrosulphite and polyvinylpyrrolidone heated to 40-90°C, cooled to room temperature, filtered, reduced to pH 6.0-7.5 with sodium hydrate solution, bottled and sterilised.

Mglur5 modulators / 2439068
Described are novel compounds of general formula I:

Agent showing serotonin 5-ht<sub>3</sub>-receptor antagonist properties

Agent showing serotonin 5-ht₃-receptor antagonist properties / 2438669
What is offered is a biologically active substance showing 5-HT3-serotonin receptor antagonist properties, 1-piperidinopropyl-2-(4-fluorophenyl)imidazo[1,2-a]benzimidazole of formula I. The compound has been known as a local anaesthetic. There are shown evident 5-HT3-antagonist properties of the compound in the macromolar concentration equal to the reference preparation ondansetron with the compound of formula I being safer.

Medication possessing antidepressive, anxiolytic and nootropic action / 2437659
Invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability.

Thiophenyl and pyrrolyl azepines as serotonin 5ht<sub>2c</sub> receptor ligands and use thereof

Thiophenyl and pyrrolyl azepines as serotonin 5ht_2c receptor ligands and use thereof / 2434872
Invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.

Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof / 2430094
Described is a novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one (phenazepam) and synthesis method thereof, which can be used in pharmaceutical industry and medicine as a tranquilliser. Said novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one is characterised by certain interplanar spacing (A0) and corresponding intensity and parameters of the crystal lattice, given in the claims.

S-adenosylmethionine compositions for peroral application / 2427376
Claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.

Alkyl sulphonamide quinolines with affinity to nk-3 receptors / 2421447
Compound is ((S)-1-phenyl-propyl)-amide 3-(methane sulphonyl amino)-2-phenyl- quinoline-4-carboxylic acid, stereoisomer, enantiomer or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on the disclosed compound.

Polymorphic modification in n-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-n-methyl-acetamide (versions), containing it pharmaceutical composition (versions), medication, method of obtaining said polymorphic modification (versions) and method of treatment and/or prevention of nervous disorders / 2413729
Claimed invention describes novel polymorphic modification N-{5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-N-methyl-acetamide, methods of its obtaining, its application as medication, its application for preparation of medication and pharmaceutical compositions, including novel polymorphic modification.

Elton mud suppositories for gynaecological and urological diseases / 2444368
Invention refers to medicine, namely a dosage form presented as suppositories for gynaecological and urological diseases. The suppositories for gynaecological and urological diseases contain a lipid complex of Elton lake mud dehydrated to 20-35%, PEG-1500 base, a preparation of Tykveol and T2 emulsifier in certain proportions, wt %.

Solid antiperspirant and/or deodorant composition in form of water-in-oil emulsion based on specific silicone emulsifiers and specific waxes, as well as method for body deodorising / 2444350
Group of inventions refers to cosmetics, particularly to means for elimination of perspiration. A solid composition and a method for preparing thereof in the form of water-in-oil emulsion contains as a cosmetically acceptable carrier: (i) at least one disperse water phase, (ii) at least one oil phase containing at least one specific wax, (iii) at least one silicone emulsifier selected from a group consisting of alkyldimeticone copolyols of formula (I) and alkyldimeticone copolyols of formula (II), as well as their mixtures, and (iv) at least one antiperspirant active component and/or one deodorant active component.

Modified adhesive composition for blade denture fixation / 2444349
Invention refers to medicine, namely to orthopaedic dentistry. An offered modified adhesive composition for blade denture fixation contains, wt %: polyvinylpyrrolidone - 5, polyacrylic acid - 15, glycerol - 4, antiseptic cetrimide - 0.01-0.03; sodium alginate - 5, fir balsam - 10, silver nanoparticles of size 1 to 5 nm - 1, distilled water - the rest. Simplicity, safety and efficacy of the developed modified adhesive composition for blade denture fixation enable to use it in common orthopaedic practice.

Method for increase of thermoresistibility of biologically active components of food and drug raw materials of vegetable and animal origin / 2444201
Invention relates to processing and food industry including animal, fish and bird feed production and may be additionally used in pharmaceutical and perfume industry during production of vitamin preparations and biologically active additives. The method for increase of thermoresistibility of biologically active components of food and drug raw materials of vegetable and animal origin envisages the raw material hydration with water from salts solution of arbitrary composition and concentration. Prior to mixing with the biomass the solution undergoes sonochemical treatment with sound pressure amplitude in the reactor no higher than the doubled hydrostatical pressure in it; one expends acoustic energy equal to 5.6 - 9.5 megajoules for treatment of the solution in an amount of one cubic metre.

Cosmetic composition using acrylate cross-linked silicone copolymer / 2443727
Disclosed cosmetic compositions contain silicone copolymers, terpolymers and higher-order polymers, which contain polyether-substituted structural units and epoxy- and oxirane structural units which react with acrylate compounds in the presence of a free-radical initiator.

Anthelminthic agent / 2443427
Invention relates to chemical-pharmaceutical industry. A herbal anthelminthic agent contains a watermelon skin powder in the amount of 0.1 g and 10.0 g and dry raw plants or dry plant extract selected from a group: wild camomile, lime blossom, acacia blossom, oak bark, St. John's wort herb and blossom, wild strawberry leaves, pot marigold blossom, nettle leaves, raspberry leaves and fruits, peppermint leaves, European walnut leaves, tansy blossom, plantain leaves, aronia fruits, common licorice root, common birch leaves, common wormwood herb, everlasting blossom, linseed, yarrow blossom, common rue leaves, Saint-Mary-thistle fruits, great burnet in the amount of 0.1 g to 2.0 g. The anthelminthic agent is non-toxic and shows advanced therapeutic properties as follows: antispasmodic, anti-inflammatory, antibacterial, detoxification, haemostatic and antiallergic. The anthelminthic agent can be presented in the form of powder, capsules, tablets. No side effects from visceral organs and intolerant responses are recognised. The agent can be used both as monotherapy, and in complex therapy.